OTC Monograph Drug User Fee Transparency Act
SB2513, titled the OTC Monograph Drug User Fee Transparency Act, would amend the Federal Food, Drug, and Cosmetic Act to increase public reporting on the Food and Drug Administration’s work on over-the-counter (OTC) monograph drugs. The bill requires FDA annual performance reports, beginning with fiscal year 2026, to include more detailed information on the agency’s progress in processing OTC monograph order requests, including the number of proposed and final orders issued for different request categories, average processing timelines, and postmarket safety activities. It also adds reporting on facility registration and whether assessed OTC monograph drug and contract manufacturing facilities paid required facility fees.
The bill further directs FDA to publish robust written minutes of negotiation meetings with regulated industry within 30 days, including substantive proposals and significant controversies or differences of opinion, while preserving existing confidentiality protections for protected or proprietary information. In addition, it requires the Government Accountability Office to study the OTC monograph drug supply chain within two years of enactment and assess supply chain stability, FDA data collection and use, interagency coordination, and whether additional authorities or information are needed to maintain supply chain stability.
The bill’s main impact would be on federal drug regulation and FDA oversight rather than on state law. It would expand statutory reporting obligations for FDA, increase transparency around OTC monograph user fee activities and negotiations, and create a new GAO review of supply chain issues affecting OTC monograph drugs. The affected parties would include FDA, OTC monograph drug manufacturers, contract manufacturing organizations, and other stakeholders in the OTC drug marketplace.
Because there are no recorded votes or committee transcripts provided, the overall sentiment can only be inferred from the bill’s structure and sponsorship: it appears to be a transparency- and oversight-focused measure rather than a controversial substantive regulatory overhaul. The bill’s emphasis on public reporting, meeting minutes, and supply chain analysis suggests a generally reform-minded approach aimed at accountability and information sharing.
The most likely points of contention would involve the scope of disclosure, the administrative burden on FDA and industry, and whether publishing detailed negotiation minutes could reveal sensitive commercial or strategic information even with confidentiality carveouts. Stakeholders focused on transparency may support the bill’s reporting requirements, while industry participants may be more cautious about expanded public disclosure and additional reporting obligations.
This bill would amend the Federal Food, Drug, and Cosmetic Act to require more detailed FDA reporting on OTC monograph drug user fee activities, public posting of negotiation meeting minutes, and a GAO study of OTC drug supply chain stability. It would not directly change state statutes, but it would expand federal oversight, transparency, and reporting obligations for FDA and regulated OTC drug manufacturers and contract manufacturing organizations.
No committee transcript or vote history is provided, so there is no recorded debate to measure. Based on the text, the bill appears to have a generally positive, oversight-oriented framing, with an emphasis on transparency, accountability, and supply chain monitoring rather than on imposing new substantive restrictions. The absence of recorded opposition or amendments suggests no documented controversy in the available materials, though the disclosure provisions could draw industry concern.
The main likely contention is over transparency versus confidentiality. The bill requires FDA to publish detailed minutes of negotiation meetings, including substantive proposals and significant disagreements, which transparency advocates would likely support but industry may view as exposing sensitive commercial information or negotiation strategy. A second possible concern is administrative burden: FDA would need to produce more detailed annual reports and track additional data on request processing, facility registration, fee payment, and postmarket safety activities, while the GAO study could also highlight gaps that imply further regulatory action.